Physician profile
Michael Magnotti
NPI 1134324585
$185,135.28
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76K · 2020: $25K · 2021: $23K · 2022: $49K · 2023: $9,512 · 2024: $2,438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Travel and Lodging: $938 · Food and Beverage: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,889.50 |
| Travel and Lodging | $938.00 |
| Food and Beverage | $121.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $70,997.29 | 2019-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $62,317.33 | 2019-2024 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24,037.24 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $12,578.65 | 2022 | |
| Merck Sharp & Dohme LLC | $11,680.00 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $2,453.70 | 2019-2021 | |
| Amgen INC. | $323.10 | 2019-2021 | |
| Radius Health, INC. | $213.57 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $132.36 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $97.18 | 2019 | |
| Janssen Scientific Affairs, LLC | $62.50 | 2019 | |
| Companion Medical, INC. | $61.28 | 2019 | |
| Insulet Corporation | $56.19 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $39.82 | 2019 | |
| Becton, Dickinson and Company | $22.68 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $22.12 | 2021 | |
| Shire North American Group INC | $21.06 | 2019 | |
| Tandem Diabetes Care, INC. | $19.21 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Magnotti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.